Invention Grant
- Patent Title: Combination and use
-
Application No.: US15537007Application Date: 2015-12-18
-
Publication No.: US10335454B2Publication Date: 2019-07-02
- Inventor: Anthony Coates , Yanmin Hu
- Applicant: HELPERBY THERAPEUTICS LIMITED
- Applicant Address: GB London, Greater London
- Assignee: HELPERBY THERAPEUTICS LIMITED
- Current Assignee: HELPERBY THERAPEUTICS LIMITED
- Current Assignee Address: GB London, Greater London
- Agency: Sughrue Mion, PLLC
- Priority: GB1422670.8 20141218; GB1500278.5 20150108; GB1521901.7 20151211
- International Application: PCT/GB2015/054069 WO 20151218
- International Announcement: WO2016/097754 WO 20160623
- Main IPC: A61K31/05
- IPC: A61K31/05 ; A61K38/12 ; A61K31/145 ; A61K31/216 ; A61K31/382 ; A61K31/405 ; A61K31/416 ; A61K31/428 ; A61K31/616 ; A61K31/135 ; A61K31/192 ; A61K31/196 ; A61K31/5415

Abstract:
The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.
Public/Granted literature
- US20170348383A1 NOVEL COMBINATION AND USE Public/Granted day:2017-12-07
Information query